Roche Bets $2.7B on Enicepatide to Challenge Tirzepatide, Facing a 4-Year Lag and Critical Data Gaps

Roche Discontinues Acmopatide, Prioritizes Enicepatide for Weight Loss

Roche has decided to discontinue the development of acmopatide (CT-868), an investigational drug for type 1 diabetes with obesity, despite its Phase 2 study successfully meeting its main goal. This strategic move aims to prioritize enicepatide (CT-388), a dual GLP-1 and GIP receptor agonist, which Roche acquired through its $2.7 billion takeover of Carmot Therapeutics. Enicepatide has demonstrated significant potential, with Phase 2 data showing weight reductions of up to 22.5% versus placebo. Roche plans a broad Phase 3 program for enicepatide covering weight loss, type 2 diabetes, and cardiovascular outcomes, with a potential regulatory submission for obesity as early as 2028.

• Roche has ceased the development of acmopatide (CT-868), an asset for type 1 diabetes with obesity, despite positive Phase 2 results. Data presented at the American Diabetes Association conference indicated a 0.34% reduction in blood A1C levels from baseline at a 4.1-mg dose, with 56% of patients achieving the recommended A1C target of under 7% compared to placebo. The decision reflects a strategic prioritization of other type 1 diabetes programs and a focus on molecules with broader multi-indication potential.
• Enicepatide (CT-388), a dual GLP-1 and GIP receptor agonist, is emerging as a leading candidate from the Carmot acquisition, showcasing best-in-class potential for weight loss. Phase 2 data revealed substantial weight reductions of up to 22.5% versus placebo, with the highest dose (24-mg) showing no plateau in weight loss over 48 weeks and no tolerability ceiling. Roche is advancing enicepatide into a comprehensive Phase 3 program for weight loss, type 2 diabetes, and cardiovascular outcomes, targeting a regulatory submission for obesity by 2028.
• The discontinuation of acmopatide is part of Roche's broader pipeline optimization following its $2.7 billion acquisition of Carmot Therapeutics, emphasizing efficiency by leveraging single molecules for multiple indications. Alongside acmopatide, Roche also announced the discontinuation of other assets, including a bispecific antibody for systemic lupus erythematosus and a mid-stage asset for diabetic macular edema. The company continues to develop petrelintide, an amylin asset partnered with Zealand Pharma, for obesity.

Roche's Bold Bet on Next-Gen GLP-1 Agonism

Roche's recent strategic maneuver—discontinuing acmopatide (CT-868) in favor of enicepatide (CT-388)—is a clear signal of the intense competition and evolving standards within the cardiometabolic therapeutic area. While acmopatide, a dual GLP-1/GIP receptor agonist, demonstrated robust glycemic control and improved lipid parameters in type 2 diabetes, its 'modest weight loss' of -2.9% appears to be the critical factor in its cessation. In an era where obesity is a growing public health threat and GLP-1 receptor agonists are proving transformative, the market demands therapies that deliver significant weight reduction alongside glycemic benefits.

This decision underscores a pivotal shift in pipeline prioritization, where 'good enough' is no longer sufficient. Roche's substantial investment in acquiring Carmot Therapeutics, and with it, enicepatide, highlights their commitment to securing a leading position with a potentially best-in-class asset. Enicepatide's impressive Phase 2 data, showing up to 22.5% weight reduction, positions it as a formidable contender against established players and other dual agonists in development. The planned broad Phase 3 program for enicepatide across obesity, type 2 diabetes, and cardiovascular outcomes reflects an ambitious strategy to make it a foundational therapy across multiple high-value indications.

However, this aggressive push is not without its challenges:

• The competitive landscape is fierce, with semaglutide already a benchmark and numerous other dual and multi-agonists advancing, demanding clear differentiation for enicepatide.

• Executing a comprehensive Phase 3 program across multiple indications with an ambitious 2028 submission target for obesity will require significant resources and flawless execution.

Ultimately, Roche is making a bold, calculated bet on enicepatide's superior efficacy to reshape its cardiometabolic portfolio and capture a significant share of this lucrative market, signaling that the bar for pipeline progression in this space has been raised considerably.